Dr Reddy's Labs unveils Sorafenib Tablets in US
Dr Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
Hyderabad: Pharma major, Dr. Reddy's Laboratories Ltd., today announced the launch of the company's Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).
Sorafenib is a kinase inhibitor indicated for the treatment of
. Unresectable hepatocellular carcinoma
. Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.
"We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories Inc.
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
Nexavar is a trademark of Bayer HealthCare Pharmaceuticals Inc.
Read also: Dr Reddys arm, Olema Pharma ink pact to develop novel cancer therapies
Read also: Dr Reddys to sell Finast, Styptovit-E and 2 other brands to Torrent Pharma
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.